Next Article in Journal
The Highly Interrelated Morbidity Respiratory Viruses Cause Among Humans and Animals in Mongolia
Next Article in Special Issue
Mycoviruses in Entomopathogenic Fungi
Previous Article in Journal
Virus Diseases of Economic Importance on Food Legumes in Africa and Their Control
Previous Article in Special Issue
Structural Analysis of Inhibitor Binding to the Feline Enteric Coronavirus (FECV) Main Protease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 17
Issue 12
10.3390/v17121556
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Minimal Polymerase-Containing Precursor Required for Chikungunya Virus RNA Synthesis

by
David Aponte-Diaz
1,
Abha Jain
1,
Jayden M. Harris
1,2,
Jamie J. Arnold
1 and
Craig E. Cameron
1,*
1
Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Viruses 2025, 17(12), 1556; https://doi.org/10.3390/v17121556
Submission received: 10 October 2025 / Revised: 25 November 2025 / Accepted: 25 November 2025 / Published: 28 November 2025
(This article belongs to the Special Issue 15-Year Anniversary of Viruses)
Browse Figures
Versions Notes

Abstract

Alphaviruses pose a growing global health threat, with Chikungunya virus (CHIKV) epidemics ongoing. Although several CHIKV vaccine candidates have progressed to late-stage clinical evaluation, none have yet achieved licensure or widespread availability. The CHIKV nonstructural proteins nsP2 and nsP4 encode essential enzymatic activities that represent key targets for antiviral development, yet the biochemical basis of nsP4 RNA-dependent RNA polymerase (RdRp) activity remains poorly understood. Here, we identify a minimal, functional precursor form of nsP4 derived from the nsP3–nsP4 polyprotein (P34) that is active in a cell-based RNA replicon system. Using synthetic, capped mRNAs, we show that cleavage of P34 by the nsP2 protease is required for robust reporter expression, and that a truncated form retaining only the C-terminal 50 residues of nsP3 (CT50-P34) supports near-wild-type replication. Unexpectedly, ubiquitin–nsP4 fusions failed to substitute for P34, likely reflecting the transient expression supported by our RNA-based system. We propose that precursor forms of nsP4 interact with the nsP1 dodecamer at the site of genome replication, where cleavage activates the RdRp and localization within the nsP1 dodecamer maintains nsP4 in its active conformation. Dissociation from the nsP1 dodecamer triggers a conformational switch to an inactive state. Together, these findings establish a tractable framework for interrogation of the assembly, activation, and regulation of the alphavirus polymerase.

1. Introduction

Alphaviruses use a polyprotein strategy to express their genome-encoded non-structural proteins [1,2,3]. The most abundant precursor is termed P123, as it is a fusion of the non-structural protein 1 (nsP1), nsP2, and nsP3 proteins [1]. Read-through of the opal stop codon present at the end of the nsP3-coding sequence produces P1234 [4]. nsP4 is the viral RNA-dependent RNA polymerase (RdRp) [5]. Among the earliest proteolytic processing pathways proposed for alphaviruses originated from studies by Hardy and Strauss, using Sindbis virus (SINV) as a model (Figure 1A) [6]. P123 is first cleaved to produce P12 and nsP3, followed by cleavage of P12 to nsP1 and nsP2. In contrast, P1234 is first cleaved to produce P12 and P34. P12 is cleaved to nsP1 and nsP2. However, P34 accumulates and exhibits a half-life of approximately 60 min [6,7,8]. Cleavage of P34 to nsP3 and nsP4 occurs over time, but nsP4 does not accumulate to high levels in cells [6,9], presumably because of the instability caused by its Tyr amino terminus and consequential degradation by the proteasome [9,10,11]. Later studies revealed an alternative pathway for processing of P1234 to P123 and nsP4 [9,12]. This processing pathway occurred early during infection and may have been restricted to early post-infection time points because precursor forms of the nsP2-encoded protease were required to cleave nsP4 from P1234 [9,12].
The observations made by the Strauss laboratory were consistent with the P34 precursor serving as the donor of the nsP4 RdRp required for genome replication and subgenomic RNA synthesis during the exponential phase of the lifecycle [1]. Additional support for using the P34 precursor as the RdRp donor came from studies by Lemm and Rice using SINV [7,13]. These studies used vaccinia virus to express precursor and processed forms of SINV non-structural proteins in various combinations. Co-expression of P123 and P34 was both necessary and sufficient to support genome replication and subgenomic RNA synthesis [7,13]. A later study by Lemm and Rice demonstrated that attachment of the carboxy-terminal 22 amino acid residues of nsP3 (referred to herein as CT22-P34) was sufficient to create a truncated form of P34 that appeared to complement P123 as efficiently as the full-length precursor. CT22-P34 complemented P123 to support genome and subgenomic RNA synthesis [7].
Subsequent investigation of CT22-P34 as the donor of the nsP4 RdRp led to the hypothesis that nsP4 had to be expressed in a form that would yield an authentic Tyr amino terminus [9]. To test this possibility, the Rice laboratory fused ubiquitin (Ub) to the amino terminus of nsP4. The resulting Ub-nsP4 fusion, paired with P123, supported genome replication and subgenomic RNA synthesis, as well as P34 precursors [12,13].
The discovery that Ub-nsP4 could substitute for P34 in plasmid/vaccinia-based trans-replication systems led many groups to deprioritize P34 as the relevant precursor in subsequent studies. In recent years, there has been minimal mention of P34, even in the description of the P1234 precursor processing pathway, since the ability of Ub-nsP4 to substitute for P34 was revealed [13]. P34 has been observed in other alphaviruses but has not been studied extensively [14,15,16]. Indeed, most studies evaluating the ability of an RdRp from one alphavirus species to substitute for that from another have used nsP4 as the Ub-nsP4 fusion [10,11,17].
We recently reported the purification of a CT50-P34 derivative from O’nyong’nyong virus (ONNV), a close relative of Chikungunya virus (CHIKV), and characterization by small-angle X-ray scattering [18]. This derivative formed a tetramer and concealed the nsP3-nsP4 cleavage site, providing a possible explanation for the previously reported slow cleavage of another alphavirus P34 from SINV [6,8,18].
This study describes the development of RNA-based replicons for CHIKV, which will permit biological analysis of the encoded non-structural proteins. In this design, the STOP2X-modified replicon lacks nsP4, so a second mRNA expressing an nsP4-containing precursor must be supplied in trans. Unlike the vaccinia- and polII/polI-driven systems reported by others in which the Ub-nsP4 fusion was an efficacious donor of the RdRp, the Ub-nsP4 fusion was a poor RdRp donor in the RNA-based replicon system. Full-length P34, CT150-P34, and CT50-P34 served as RdRp donors. We discuss potential reasons for the discrepancy and the implications of our findings on our understanding of alphavirus biology derived from the use of more permissive replicons.

2. Materials and Methods

Cell culture. HeLa cells (CRM-CCL-2; ATCC, Manassas, VA, USA) were maintained in Dulbecco’s Modified Eagle Medium: Ham’s F-12 nutrient mixture (DMEM/F12; Gibco, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS; Atlanta Biologics, Flowery Branch, GA, USA) and 1% penicillin-streptomycin (P/S; Corning, Corning, NY, USA). Cells were cultured at 37 °C in a humidified incubator with 5% CO2.
Plasmids. Insertions and deletions were generated by overlap extension PCR or synthesized as gBlocks (Integrated DNA Technologies, IDT, Coralville, IA, USA). Constructs were assembled using In-Fusion seamless cloning (Takara, San Jose, CA, USA). All insertions, deletions, or point mutations were verified by Sanger sequencing (short fragments) or Oxford Nanopore long-read sequencing (whole plasmids). rCHIKV constructs derived from published sequences (GenBank accessions GU189061 and EF452493). Bicistronic constructs incorporated the human β-globin sequence (U01317) and the EMCV IRES, as described by Bochkov et al. (2006) [19].
In vitro transcription. Plasmids encoding rCHIKV genomes (full-length or replicon) were linearized with NotI, and BiCis constructs with SalI positioned immediately downstream of the encoded poly(A) tail. Linearized templates were transcribed in vitro using T7 RNA polymerase produced in-house (Cameron Lab). Reactions were treated with 2 U Turbo DNase (ThermoFisher, Waltham, MA, USA) to remove residual DNA. rCHIKV RNAs were co-transcriptionally capped with CleanCap AU (TriLink, San Diego, CA, USA), while BiCis RNAs were capped with CleanCap AG (TriLink). Transcripts were purified with the RNeasy Mini Kit (Qiagen, Germantown, MD, USA), quantified spectrophotometrically, and resuspended in RNase-free water. Purified RNAs were delivered into cells by electroporation (Gene Pulser, Bio-Rad, Hercules, CA, USA).
Subgenomic replicon luciferase assay. Luciferase assays were performed as described previously [20]. Briefly, 5 µg of in vitro–transcribed replicon RNA was electroporated into HeLa cells, which were then cultured in standard growth medium. At the indicated times post-electroporation, cells were harvested and lysed in 100 µL of 1× Cell Culture Lysis Reagent (CCLR; Promega, Madison, WI, USA). Luciferase activity, as a surrogate for subgenomic RNA replication, was measured in lysates after addition of an equal volume of Nano-Glo or Firefly Luciferase substrate (Promega). Luminescence was quantified using either a Junior LB 9509 luminometer (Berthold Technologies, Oak Ridge, TN, USA) or a BioTek plate reader (Agilent, Winooski, VT, USA).
Antibodies. Primary antibody: rabbit anti-α-tubulin (Cell Signaling, Danvers, MA, USA; 1:500). Secondary antibody: goat anti-rabbit IgG (H+L) conjugated to Alexa Fluor dyes (Invitrogen, Waltham, MA, USA; 1:1000), used for immunofluorescence.
Immunofluorescence. Immunofluorescence assays were performed as described previously [21]. HeLa cells were grown on glass coverslips, treated as described in the respective figure legends, and fixed with 4% paraformaldehyde in PBS for 20 min at the indicated time points. For UnaG reporter detection, cells were supplemented with 7 µM bilirubin (APEX Bio, Houston, TX, USA) to enhance fluorescence. Cells were permeabilized with 0.2% Triton X-100 in PBS (10 min), blocked with 3% goat serum (1 h), and incubated with primary antibodies (1 h). Following washes, coverslips were incubated with secondary antibodies (1 h) and counterstained with either DAPI (Sigma, St. Louis, MO, USA) or TO-PRO-3 (Invitrogen) for 10 min. Coverslips were mounted in ProLong Glass Antifade Mountant (ThermoFisher).
Imaging. Fluorescence imaging was performed on a BZ-X800 all-in-one microscope (Keyence, Itasca, IL, USA) using a 40× objective. Images were processed with the BZ-X800 Analyzer software (Version 1.1.2.4, Keyence). Multiple images were acquired, and representative cells were selected for display.

3. Results

3.1. CHIKV Replicon Used in This Study

The alphavirus genome encodes two open reading frames: ORF-1 and ORF-2 (Figure 1B). ORF-1 encodes the non-structural proteins responsible for genome replication. ORF-2 encodes the structural proteins responsible for virion morphogenesis. ORF-1 is translated in a cap-dependent manner using full-length genomes, while ORF-2 is translated in a cap-dependent manner from a subgenomic RNA. It is well established that ORF-2 can be eliminated without consequence to the kinetics of genomic or subgenomic RNA synthesis [22]. We substituted ORF2 with nanoluciferase (nLuc)-coding sequence between the genetically encoded start and stop codons (Figure 1B) [23].
Our initial cDNA construct encoded a bacteriophage SP6 promoter (Figure 1C). Transcription initiation by this RNA polymerase requires that the first nucleotide incorporated is guanosine monophosphate (GMP) [24]. However, the first nucleotide of alphavirus genomes is adenosine monophosphate (AMP) [25]. Therefore, use of SP6 RNA polymerase (SP6) produces an RNA without an authentic 5′-end [24]. We also created a cDNA that utilized a bacteriophage T7 promoter, allowing T7 RNA polymerase (T7) to produce an authentic 5′-end when using the CleanCap® AU cap analog (AU, Figure 1C). The AU cap analog is compatible only with a T7 promoter, not with an SP6 promoter.
To ensure the addition of an m7G cap to the 5′-end, we used cap analogs to initiate transcription [26]. For SP6, we used ARCA; for T7, we used CleanCap® AU (Figure 1D) [27]. We transfected ARCA-capped (5′-GA) or CleanCap® AU-capped (5′-AU) RNA into HeLa cells and measured luciferase activity as a function of time post-transfection. The RNA with an authentic cap replicated faster than the one lacking it (Figure 1E). Replication of the RNA with the authentic cap required the encoded polymerase, because converting the catalytic site GDD to GAA eliminated RNA synthesis (GAA in Figure 1E).
We also constructed a subgenomic replicon encoding the fluorescent green UnaG reporter [28] (Figure 1F). Transfection of the CleanCap® AU-capped UnaG reporter RNA into HeLa cells led to expression of UnaG (Figure 1F). Colocalization with tubulin was consistent with accumulation of UnaG in the cytoplasm (Figure 1F).

3.2. Strategy to Express CHIKV Proteins to Complement Replicating Subgenomic RNA Replicons in Trans

The goal of this study was to determine the form(s) of CHIKV nsP4 or P34 used for RNA synthesis in cells. We constructed a cDNA that would direct the expression of bicistronic (BiCis) mRNA using T7 and CleanCap® AG. The 5′- and 3′-untranslated regions were taken from human β-globin mRNA, which should confer stability to the RNA (panel i of Figure 2A) [29]. We designed the expression cassette to permit the first cistron (ORF-A) to be changed easily and the second cistron to encode enhanced green fluorescent protein (eGFP in panel i of Figure 2A) [30]. The cap directs translation of ORF-A. Translation of eGFP is driven by encephalomyocarditis virus internal ribosome entry site (EMCV IRES in panel i of Figure 2A) [19]. To optimize transfection conditions, we introduced the coding sequence for the photostable red fluorescent protein, TagRFP-T, into the first cistron (panel ii of Figure 2A) [31]. Transfection of the bicistronic mRNA encoding both fluorescent proteins produced strong signals for both proteins (panel iii of Figure 2A).
The second experiment we performed assessed the kinetics of gene expression after inserting genes into the first cistron. To do this quantitatively, we used luciferase reporters. To compare differences in gene sequences, we introduced either nLuc or firefly luciferase (FLuc) (panel i of Figure 2B). Both reporters reached near-maximum expression levels by 2 h post-transfection (hpt) (panel ii of Figure 2B). The dynamic range of nLuc was 10-fold greater than observed for FLuc (panel ii of Figure 2B).
The goal was to recapitulate the Lemm and Rice experiment, co-expressing P123 and P34. P34 would be expressed using the bicistronic mRNA. The possibility existed that co-transfection of the mRNA and the subgenomic replicon would compete for the translation machinery. To test this possibility directly, we co-transfected the CHIKV subgenomic replicon encoding nLuc with the BiCis TagRFP-T mRNA. The kinetics of luciferase activity were the same in the absence and presence of the BiCis mRNA (Figure 2C). We conclude that there is no competition between these two RNAs when introduced into the cell.
Production of the P1234 precursor requires read-through of an opal (UGA) stop codon at the 3′-end of the nsP3-coding sequence [4]. To construct a subgenomic mRNA that would only produce P123, we substituted the opal stop codon with ochre (UAA) and opal (UGA) stop codons. This mRNA is referred to as rCHIKV-STOP2X (Figure 2D). Transfection of this mRNA into cells failed to produce any detectable luciferase activity (Figure 2C).

3.3. Expression of CHIKV P123 and P34 Is Sufficient for Subgenomic RNA Synthesis

We were now able to repeat the experiment performed by Lemm and Rice with SINV [7] using CHIKV. We co-transfected rCHIKV-STOP2X and BiCis-P34 mRNAs to produce P123 and P34 precursor proteins (Figure 3A). These proteins supported minus-strand synthesis followed by genomic and subgenomic RNA synthesis (Figure 3B). The subgenomic RNA encodes nLuc, so we indirectly monitored subgenomic RNA synthesis by measuring luciferase activity (Figure 3B). Transfection of STOP2X mRNA alone yielded no luciferase signal (STOP2X in Figure 3C). In combination with P34 mRNA, however, luciferase activity was observed beginning at 2 h post-transfection (STOP2X + P34 WT in Figure 3C). The observed kinetics were on par with the kinetics observed for the complete CHIKV replicon (rCHIKV-sg-nLuc WT in Figure 3C). Production of luciferase activity required the nsP4 domain of P34 to be an active RdRp, as mutation of the signature GDD motif to GAA precluded production of luciferase activity (STOP2X + P34 GAA in Figure 3C). We observed a dependency on the amount of P34 mRNA delivered with the STOP2X for complementation as assessed by luciferase activity (Figure 3D). Inactivating nsP2-dependent proteolysis of P34 (Figure 3E) eliminated complementation (Figure 3F).

3.4. Identification of a Minimal P34 Precursor for Subgenomic RNA Synthesis

The nsP3 domain of P34 is a multifunctional protein. At the amino terminus, there is a macro domain-containing mono-ADP-ribosylhydrolase activity (MD in Figure 4A) [32], followed by an alphavirus unique domain of unknown function (AUD in Figure 4A) [33], and ending with a hypervariable domain (HVD) that is an intrinsically disordered domain contributing to myriad interactions with the host that contribute positively to alphavirus multiplication (Figure 4A) [34,35,36]. For SINV, the nsP3 domain of P34 is 549 amino acids [1]. Lemm and Rice showed that addition of only 22–153 amino acids from the carboxyl terminus of nsP3 to nsP4 was sufficient for complementation [7,12]. These truncated forms of P34 appeared to be equivalent functionally, at least within the sensitivity of the assays used [7,12].
We performed a similar experiment for CHIKV. We started with a P34 derivative containing only the carboxy-terminal 150 amino acids of nsP3. This derivative was named CT150-P34. In addition to this derivative, we constructed CT50-P34 and CT39-P34. CT50-P34 includes the last 50, and CT39-P34 contains the last 39 amino acids of nsP3, respectively. All of these derivatives exhibited some level of activity (Figure 4B). Luciferase activity produced by CT150-P34 essentially superimposed with P34 (Figure 4B). CT50-P34 exhibited a shorter lag in luciferase accumulation than P34, but reached endpoints that were very similar (Figure 4B). CT39-P34 exhibited a reproducible ~1–1.5 log reduction and delayed onset of activity relative to CT50-P34, indicating an essential contribution from residues 40–50 for efficient polymerase activation. The CT50-P34 derivative is currently under investigation [18].

3.5. Ub-nsP4 Fusions Do Substitute for P34 When Expressed Transiently

The early studies of Lemm and Rice showed that the authentic tyrosine amino terminus of nsP4 supports the most efficient synthesis of SINV RNAs [7,25]. Since that time, the lab of Andres Merits has reinforced this conclusion for many other alphaviruses [37]. To produce Tyr•nsP4, these investigators fused Tyr•nsP4 to ubiquitin (Ub) to create Ub-Tyr•nsP4 (Figure 5A). Ubiquitin carboxy-terminal hydrolases remove Ub cleanly, likely co-translationally, to release Tyr•nsP4 (Figure 5A) [38,39]. Unexpectedly, Ub-Tyr•nsP4 did not substitute well for P34 (Figure 5B). Some luciferase activity was detected, but Ub-Tyr•nsP4 exhibited an extreme delay of at least 5 h before luciferase activity was detected (Figure 5B). At 10 h post-transfection, this derivative was still at a level of luciferase activity more than 3-logs lower than observed for P34 (Figure 5B). The activity for Ub-Tyr•nsP4 required ubiquitin cleavage, as the cleavage-resistant derivative was inactive (Ub*-Tyr•nsP4 in Figure 5B). A pre-processed form of nsP4, Met•Tyr•nsP4, also failed to support RNA synthesis and consequently luciferase activity (Figure 5B). As discussed below, the inability of the Ub-Tyr•nsP4 to function in our system is likely attributable to the transient nature of expression and/or levels of the fusion that accumulate in cells.

4. Discussion

Alphaviruses are a persistent and growing threat to public health [40]. Epidemics of Chikungunya virus (CHIKV) are currently ongoing [41]. The safety of existing vaccines to prevent CHIKV infection and/or the sequelae associated with infection is questionable [42,43]. The development of antivirals to address infections caused by CHIKV and other alphaviruses is urgently needed for therapy. The nsP2-encoded protease [8,44], ATPase and helicase [45], and the nsP4-encoded RNA-dependent RNA polymerase (RdRp) [15,46] represent important targets for the development of antiviral therapeutics. The biochemical assays to study the nsP2-encoded activities are well established [10,47]. However, the ability to study kinetics, mechanism, and inhibition of the nsP4-encoded RdRp in vitro does not exist. The goal of this study was to identify a minimal CHIKV nsP4 form that is active in a cell-based system, thereby making it tractable for biochemical and biophysical characterization.
Early studies from the Strauss and Rice laboratories showed that a polyprotein precursor form of nsP4, specifically P34, an nsP3-nsP4 polyprotein, could support genome replication when co-expressed with the P123 polyprotein precursor [6,9]. Data from the Rice laboratory suggested that precursor forms of nsP4 were essential because an authentic tyrosine amino terminus of nsP4 was required for genome replication [7,12,25]. Expression of a ubiquitin-nsP4 fusion complemented P123 as well as P34 in experiments from his lab [7,12] and others [16,17,48]. However, nsP4 with an authentic amino terminus lacks any demonstrable RdRp activity in vitro [5,17,49] and, at best, has been shown to exhibit terminal transferase activity [5]. Biophysical studies performed by our laboratory using the O’nyong’nyong virus (ONNV) nsP4 RdRp with an authentic tyrosine amino terminus revealed an unexpected, extended conformation that explained the absence of demonstrable polymerase activity for this form of the protein [18].
Previous studies evaluating the activity of nsP4 precursor proteins in genome replication have constitutively overexpressed these proteins using either a vaccinia virus expressing bacteriophage T7 RNA polymerase [7,13] or the cellular RNA polymerase II (RNAPII) driven by a cytomegalovirus (CMV) promoter [17,22,50]. The presence of vaccinia virus in a cell where alphavirus genome replication was being monitored was state-of-the-art in the 1990s but is now considered a confounding factor. The use of vaccinia-T7 introduces high-level constitutive expression and virus-induced changes in cell physiology, which could mask precursor-specific regulation. The use of RNAPII requires transfecting DNA and, at a minimum, tens of hours for expression to occur [22,51,52].
We opted to use an RNA-based system. Delivery of viral or recombinant mRNAs to the cytoplasm results in expression within minutes, as observed during a bona fide viral infection. In addition, the technology to suppress, if not eliminate, activation of innate immune sensors by transfected mRNA continues to improve [51,53,54,55]. Transfection of CHIKV mRNA with an authentic, capped, AU 5′-end encoding P1234 and nLuc in place of the coding sequence for the structural proteins yielded a near 5-log increase in luciferase over a 10 h period (Figure 1). rCHIKV (AU) mRNA transfection avoids the confounding effects of vaccinia or CMV/T7 nuclear expression systems, prevents DNA-related innate immune activation and provides controlled, transient expression, enabling us to unmask differences missed in constitutive overexpression systems. We constructed a bicistronic mRNA for expressing nsP4 derivatives, which we validated by inserting the coding sequences for two different luciferase enzymes (Figure 2). Co-expression of the CHIKV P123 precursor instead of the P1234 precursor and the CHIKV P34 precursor was sufficient to produce levels of luciferase activity equivalent to the primary CHIKV replicon (Figure 3). Luciferase activity correlated linearly with the amount of P34 expressed to a limit (Figure 3). Cleavage of P34 by the nsP2-encoded protease was essential to observe luciferase activity (Figure 3). Removal of all nsP3 except for the 50 carboxy-terminal residues (CT50-P34) supported near wild-type levels of luciferase activity (Figure 4).
Expression of P34 in bacteria results in substantial cleavage of the protein by bacterial proteases, which target the very large, intrinsically disordered domain (our unpublished observations). Once we learned that CHIKV CT50-P34 functioned in cells, we expressed and purified ONNV CT50-P34 [18]. Unlike nsP4, which forms an extended conformation, CT50-P34 forms a compact conformation and assembles into tetramers [18]. Our working hypothesis is that P34 and functional derivatives thereof bind to the central channel of an nsP1 dodecamer (Figure 6A). nsP2 cleaves the (nsP1)12-bound P34, activating its RdRp activity (Figure 6B). Physical interactions between nsP4 and (nsP1)12 maintain nsP4 in its active conformation (Figure 6B). Once RNA synthesis is complete, dissociation of nsP4 from (nsP1)12 causes a fold switch to the extended, inactive conformation (Figure 6C). This change may prevent the RdRp from using cellular RNA to produce dsRNA that would activate intrinsic defense mechanisms and innate immune responses of the cell [56,57,58].
The one unexpected observation of the experiments reported here was the inability to have a Ub-nsP4 fusion substitute for P34, as observed by other laboratories (Figure 5). Ub fusions are generally co-translationally processed unless sufficient fusion protein is made to overwhelm the ubiquitin-specific carboxy-terminal hydrolases [7,17,39]. Expression of Ub-nsP4 using the bicistronic mRNA approach may be high initially but will diminish over time as the mRNA is degraded and nsP4 undergoes turnover [57]. The systems in which Ub-nsP4 has been shown to work constitutively express the fusion protein, which is the simplest explanation for the difference between the systems.
In conclusion, we have established an RNA-based replicon and trans-complementation system for CHIKV that should be broadly applicable to alphaviruses. The primary benefit of this approach is its speed, which is faster than that of DNA-based approaches. Using this system, we have defined the CT50-P34 precursor as the minimal donor of CHIKV nsP4 RdRp activity, consistent with findings for SINV [7,18,59]. The capacity to purify the ONNV CT50-P34 derivative [18] bodes well for the purification of CHIKV CT50-P34. The ability to use biological, biochemical, and biophysical approaches to study CHIKV genome replication represents a significant advancement that will likely fill decades-old gaps in our understanding of alphavirus genome replication.

4.1. Limitations of the Study

We have been unable to directly quantify the expression of nsP4 or polyproteins thereof because all antibodies against nsP4 have exhibited very high backgrounds. This circumstance is likely to change with the use of our purified preparations of nsP4 and CT50-P34 as antigens. In future studies, the addition of immunological tags to the nsP4-coding sequence may facilitate detection of nsP4 and its precursors.
We are only monitoring subgenomic RNA synthesis using the replicons reported in this study. The assumption is that minus- and full-length genomic RNA synthesis are also occurring. While minus-strand synthesis cannot be monitored using reporters, future versions of the reported replicon will benefit from addition of a reporter to the P123 open reading frame.

4.2. Perspectives

The RNA-based replicon used here will permit a rapid assessment of the determinants of the CHIKV genome required for RNA synthesis. The system reported herein should enable the discovery of determinants of CT50-P34 required for complementation. Additionally, interactions between various forms of nsP4 and other non-structural proteins can be examined. Addressing these fundamental questions may permit reconstitution of the CHIKV replisome in vitro from purified components and pave the way for the first mechanistic description of nucleotide addition by an alphavirus polymerase.

Author Contributions

Conceptualization: D.A.-D., J.J.A. and C.E.C.; data collection and acquisition: D.A.-D., A.J. and J.M.H.; data analysis: D.A.-D., A.J. and C.E.C.; data interpretation: D.A.-D., J.J.A. and C.E.C.; contributed new reagents or analytical tools: D.A.-D., A.J. and J.M.H.; visualization & figures: D.A.-D. and C.E.C.; writing—original draft: D.A.-D. and C.E.C.; writing—review & editing: D.A.-D., A.J., J.M.H., J.J.A. and C.E.C.; supervision: D.A.-D. and C.E.C.; project administration: D.A.-D. and C.E.C.; funding acquisition: J.J.A. and C.E.C. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by grants from the National Institutes of Health (NIH), including the following: R01 AI045818 to C.E.C. and J.J.A.; U19 AI171292 Core C to C.E.C.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request.

Acknowledgments

The corresponding author thanks members of our lab and collaborators for their feedback on the progression of these studies. The authors also thank Che-Kang Chang and Mark Heise for sharing plasmids and the original CHIKV sequences.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Strauss, J.H.; Strauss, E.G. The Alphaviruses: Gene Expression, Replication, and Evolution. Microbiol. Rev. 1994, 58, 491–562. [Google Scholar] [CrossRef] [PubMed]
  2. Howley, P.M.; Knipe, D.M. Fields Virology. Volume 1, Emerging Viruses; Lippincott Williams & Wilki: Philadelphia, PA, USA, 2021. [Google Scholar]
  3. Ahola, T.; McInerney, G.; Merits, A. Alphavirus RNA Replication in Vertebrate Cells. Adv. Virus Res. 2021, 111, 111–156. [Google Scholar] [CrossRef] [PubMed]
  4. Li, G.P.; Rice, C.M. Mutagenesis of the In-Frame Opal Termination Codon Preceding nsP4 of Sindbis Virus: Studies of Translational Read-through and Its Effect on Virus Replication. J. Virol. 1989, 63, 1326–1337. [Google Scholar] [CrossRef] [PubMed]
  5. Tomar, S.; Hardy, R.W.; Smith, J.L.; Kuhn, R.J. Catalytic Core of Alphavirus Nonstructural Protein nsP4 Possesses Terminal Adenylyltransferase Activity. J. Virol. 2006, 80, 9962–9969. [Google Scholar] [CrossRef]
  6. Hardy, W.R.; Strauss, J.H. Processing the Nonstructural Polyproteins of Sindbis Virus: Study of the Kinetics in Vivo by Using Monospecific Antibodies. J. Virol. 1988, 62, 998–1007. [Google Scholar] [CrossRef]
  7. Lemm, J.A.; Rice, C.M. Assembly of Functional Sindbis Virus RNA Replication Complexes: Requirement for Coexpression of P123 and P34. J. Virol. 1993, 67, 1905–1915. [Google Scholar] [CrossRef]
  8. Hardy, W.R.; Strauss, J.H. Processing the Nonstructural Polyproteins of Sindbis Virus: Nonstructural Proteinase Is in the C-Terminal Half of nsP2 and Functions Both in Cis and in Trans. J. Virol. 1989, 63, 4653–4664. [Google Scholar] [CrossRef]
  9. Shirako, Y.; Strauss, J.H. Regulation of Sindbis Virus RNA Replication: Uncleaved P123 and nsP4 Function in Minus-Strand RNA Synthesis, Whereas Cleaved Products from P123 Are Required for Efficient plus-Strand RNA Synthesis. J. Virol. 1994, 68, 1874–1885. [Google Scholar] [CrossRef]
  10. Vasiljeva, L.; Merits, A.; Golubtsov, A.; Sizemskaja, V.; Kääriäinen, L.; Ahola, T. Regulation of the Sequential Processing of Semliki Forest Virus Replicase Polyprotein. J. Biol. Chem. 2003, 278, 41636–41645. [Google Scholar] [CrossRef]
  11. Varshavsky, A. The N-End Rule: Functions, Mysteries, Uses. Proc. Natl. Acad. Sci. USA 1996, 93, 12142–12149. [Google Scholar] [CrossRef]
  12. Lemm, J.A.; Rümenapf, T.; Strauss, E.G.; Strauss, J.H.; Rice, C.M. Polypeptide Requirements for Assembly of Functional Sindbis Virus Replication Complexes: A Model for the Temporal Regulation of Minus- and Plus-strand RNA Synthesis. EMBO J. 1994, 13, 2925–2934. [Google Scholar] [CrossRef]
  13. Lemm, J.A.; Bergqvist, A.; Read, C.M.; Rice, C.M. Template-Dependent Initiation of Sindbis Virus RNA Replication In Vitro. J. Virol. 1998, 72, 6546–6553. [Google Scholar] [CrossRef] [PubMed]
  14. Pietilä, M.K.; Albulescu, I.C.; van Hemert, M.J.; Ahola, T. Polyprotein Processing as a Determinant for In Vitro Activity of Semliki Forest Virus Replicase. Viruses 2017, 9, 292. [Google Scholar] [CrossRef] [PubMed]
  15. Pietilä, M.K.; Hellström, K.; Ahola, T. Alphavirus Polymerase and RNA Replication. Virus Res. 2017, 234, 44–57. [Google Scholar] [CrossRef] [PubMed]
  16. Spuul, P.; Balistreri, G.; Hellström, K.; Golubtsov, A.V.; Jokitalo, E.; Ahola, T. Assembly of Alphavirus Replication Complexes from RNA and Protein Components in a Novel Trans-Replication System in Mammalian Cells. J. Virol. 2011, 85, 4739–4751. [Google Scholar] [CrossRef]
  17. Utt, A.; Quirin, T.; Saul, S.; Hellström, K.; Ahola, T.; Merits, A. Versatile Trans-Replication Systems for Chikungunya Virus Allow Functional Analysis and Tagging of Every Replicase Protein. PLoS ONE 2016, 11, e0151616. [Google Scholar] [CrossRef]
  18. Arnold, J.J.; Braet, S.M.; Vieira, L.C.; Moustafa, I.M.; Gohara, D.W.; Fecko, J.A.; Su, Y.-W.N.; Jain, A.; Aponte-Diaz, D.; Wilke, C.O.; et al. A Fold Switch Regulates Conformation of an Alphavirus Virus RNA-Dependent RNA Polymerase. bioRxiv 2025. bioRxiv:2025.09.18.676892. [Google Scholar] [CrossRef]
  19. Bochkov, Y.A.; Palmenberg, A.C. Translational Efficiency of EMCV IRES in Bicistronic Vectors Is Dependent upon IRES Sequence and Gene Location. BioTechniques 2006, 41, 283–292. [Google Scholar] [CrossRef]
  20. Oh, H.S.; Banerjee, S.; Aponte-Diaz, D.; Sharma, S.D.; Aligo, J.; Lodeiro, M.F.; Ning, G.; Sharma, R.; Arnold, J.J.; Cameron, C.E. Multiple Poliovirus-Induced Organelles Suggested by Comparison of Spatiotemporal Dynamics of Membranous Structures and Phosphoinositides. PLoS Pathog. 2018, 14, e1007036. [Google Scholar] [CrossRef]
  21. Aponte-Diaz, D.; Harris, J.M.; Kang, T.E.; Korboukh, V.; Sotoudegan, M.S.; Gray, J.L.; Yennawar, N.H.; Moustafa, I.M.; Macadam, A.; Cameron, C.E. Non-Lytic Spread of Poliovirus Requires the Nonstructural Protein 3CD. mBio 2024, 16, e03276-24. [Google Scholar] [CrossRef]
  22. Frolov, I.; Frolova, E.; Schlesinger, S. Sindbis Virus Replicons and Sindbis Virus: Assembly of Chimeras and of Particles Deficient in Virus RNA. J. Virol. 1997, 71, 2819–2829. [Google Scholar] [CrossRef]
  23. Sun, C.; Gardner, C.L.; Watson, A.M.; Ryman, K.D.; Klimstra, W.B. Stable, High-Level Expression of Reporter Proteins from Improved Alphavirus Expression Vectors To Track Replication and Dissemination during Encephalitic and Arthritogenic Disease. J. Virol. 2013, 88, 2035–2046. [Google Scholar] [CrossRef] [PubMed]
  24. Stump, W.T.; Hall, K.B. SP6 RNA Polymerase Efficiently Synthesizes RNA from Short Double-Stranded DNA Templates. Nucleic Acids Res. 1993, 21, 5480–5484. [Google Scholar] [CrossRef] [PubMed]
  25. Shirako, Y.; Strauss, E.G.; Strauss, J.H. Modification of the 5′ Terminus of Sindbis Virus Genomic RNA Allows nsP4 RNA Polymerases with Nonaromatic Amino Acids at the N Terminus To Function in RNA Replication. J. Virol. 2003, 77, 2301–2309. [Google Scholar] [CrossRef] [PubMed]
  26. Grudzien-Nogalska, E.; Stepinski, J.; Jemielity, J.; Zuberek, J.; Stolarski, R.; Rhoads, R.E.; Darzynkiewicz, E. Synthesis of Anti-Reverse Cap Analogs (ARCAs) and Their Applications in mRNA Translation and Stability. Methods Enzym. 2007, 431, 203–227. [Google Scholar] [CrossRef]
  27. Henderson, J.M.; Ujita, A.; Hill, E.; Yousif-Rosales, S.; Smith, C.; Ko, N.; McReynolds, T.; Cabral, C.R.; Escamilla-Powers, J.R.; Houston, M.E. Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription. Curr. Protoc. 2021, 1, e39. [Google Scholar] [CrossRef]
  28. Kumagai, A.; Ando, R.; Miyatake, H.; Greimel, P.; Kobayashi, T.; Hirabayashi, Y.; Shimogori, T.; Miyawaki, A. A Bilirubin-Inducible Fluorescent Protein from Eel Muscle. Cell 2013, 153, 1602–1611. [Google Scholar] [CrossRef]
  29. Russell, J.E.; Liebhaber, S.A. The Stability of Human Beta-Globin mRNA Is Dependent on Structural Determinants Positioned within Its 3’ Untranslated Region. Blood 1996, 87, 5314–5323. [Google Scholar] [CrossRef]
  30. Cormack, B.P.; Valdivia, R.H.; Falkow, S. FACS-Optimized Mutants of the Green Fluorescent Protein (GFP). Gene 1996, 173, 33–38. [Google Scholar] [CrossRef]
  31. Shaner, N.C.; Lin, M.Z.; McKeown, M.R.; Steinbach, P.A.; Hazelwood, K.L.; Davidson, M.W.; Tsien, R.Y. Improving the Photostability of Bright Monomeric Orange and Red Fluorescent Proteins. Nat. Methods 2008, 5, 545–551. [Google Scholar] [CrossRef]
  32. Malet, H.; Coutard, B.; Jamal, S.; Dutartre, H.; Papageorgiou, N.; Neuvonen, M.; Ahola, T.; Forrester, N.; Gould, E.A.; Lafitte, D.; et al. The Crystal Structures of Chikungunya and Venezuelan Equine Encephalitis Virus nsP3 Macro Domains Define a Conserved Adenosine Binding Pocket. J. Virol. 2009, 83, 6534–6545. [Google Scholar] [CrossRef]
  33. Gao, Y.; Goonawardane, N.; Ward, J.; Tuplin, A.; Harris, M. Multiple Roles of the Non-Structural Protein 3 (nsP3) Alphavirus Unique Domain (AUD) during Chikungunya Virus Genome Replication and Transcription. PLoS Pathog. 2019, 15, e1007239. [Google Scholar] [CrossRef] [PubMed]
  34. Meshram, C.D.; Shiliaev, N.; Frolova, E.I.; Frolov, I. Hypervariable Domain of nsP3 of Eastern Equine Encephalitis Virus Is a Critical Determinant of Viral Virulence. J. Virol. 2020, 94, e00617-20. [Google Scholar] [CrossRef] [PubMed]
  35. Foy, N.J.; Akhrymuk, M.; Akhrymuk, I.; Atasheva, S.; Bopda-Waffo, A.; Frolov, I.; Frolova, E.I. Hypervariable Domains of nsP3 Proteins of New World and Old World Alphaviruses Mediate Formation of Distinct, Virus-Specific Protein Complexes. J. Virol. 2012, 87, 1997–2010. [Google Scholar] [CrossRef] [PubMed]
  36. Abdullah, N.; Ahemad, N.; Aliazis, K.; Khairat, J.E.; Lee, T.C.; Ahmad, S.A.A.; Adnan, N.A.A.; Macha, N.O.; Hassan, S.S. The Putative Roles and Functions of Indel, Repetition and Duplication Events in Alphavirus Non-Structural Protein 3 Hypervariable Domain (nsP3 HVD) in Evolution, Viability and Re-Emergence. Viruses 2021, 13, 1021. [Google Scholar] [CrossRef]
  37. Lello, L.S.; Bartholomeeusen, K.; Wang, S.; Coppens, S.; Fragkoudis, R.; Alphey, L.; Ariën, K.K.; Merits, A.; Utt, A. nsP4 Is a Major Determinant of Alphavirus Replicase Activity and Template Selectivity. J. Virol. 2021, 95, e00355-21. [Google Scholar] [CrossRef]
  38. Ronau, J.A.; Beckmann, J.F.; Hochstrasser, M. Substrate Specificity of the Ubiquitin and Ubl Proteases. Cell Res. 2016, 26, 441–456. [Google Scholar] [CrossRef]
  39. Komander, D.; Clague, M.J.; Urbé, S. Breaking the Chains: Structure and Function of the Deubiquitinases. Nat. Rev. Mol. Cell Biol. 2009, 10, 550–563. [Google Scholar] [CrossRef]
  40. Rupp, J.C.; Sokoloski, K.J.; Gebhart, N.N.; Hardy, R.W. Alphavirus RNA Synthesis and Non-Structural Protein Functions. J. Gen. Virol. 2015, 96, 2483–2500. [Google Scholar] [CrossRef]
  41. Powers, A.M.; Logue, C.H. Changing Patterns of Chikungunya Virus: Re-Emergence of a Zoonotic Arbovirus. J. Gen. Virol. 2007, 88, 2363–2377. [Google Scholar] [CrossRef]
  42. Shaikh, M.S.; Faiyazuddin, M.; Khan, M.S.; Pathan, S.K.; Syed, I.J.; Gholap, A.D.; Akhtar, M.S.; Sah, R.; Mehta, R.; Sah, S.; et al. Chikungunya Virus Vaccine: A Decade of Progress Solving Epidemiological Dilemma, Emerging Concepts, and Immunological Interventions. Front. Microbiol. 2024, 15, 1413250. [Google Scholar] [CrossRef]
  43. Maure, C.; Khazhidinov, K.; Kang, H.; Auzenbergs, M.; Moyersoen, P.; Abbas, K.; Santos, G.M.L.; Medina, L.M.H.; Wartel, T.A.; Kim, J.H.; et al. Chikungunya Vaccine Development, Challenges, and Pathway toward Public Health Impact. Vaccine 2024, 42, 126483. [Google Scholar] [CrossRef] [PubMed]
  44. Sawicki, D.L.; Sawicki, S.G. A Second Nonstructural Protein Functions in the Regulation of Alphavirus Negative-Strand RNA Synthesis. J. Virol. 1993, 67, 3605–3610. [Google Scholar] [CrossRef] [PubMed]
  45. de Cedrón, M.G.; Ehsani, N.; Mikkola, M.L.; García, J.A.; Kääriäinen, L. RNA Helicase Activity of Semliki Forest Virus Replicase Protein NSP2. FEBS Lett. 1999, 448, 19–22. [Google Scholar] [CrossRef] [PubMed]
  46. Yin, P.; May, N.A.; Lello, L.S.; Fayed, A.; Parks, M.G.; Drobish, A.M.; Wang, S.; Andrews, M.; Sticher, Z.; Kolykhalov, A.A.; et al. 4′-Fluorouridine Inhibits Alphavirus Replication and Infection In Vitro and In Vivo. mBio 2024, 15, e00420-24. [Google Scholar] [CrossRef]
  47. Wang, S.; Mahalingam, S.; Merits, A. Alphavirus nsP2: A Multifunctional Regulator of Viral Replication and Promising Target for Anti-Alphavirus Therapies. Rev. Méd. Virol. 2025, 35, e70030. [Google Scholar] [CrossRef]
  48. Rausalu, K.; Utt, A.; Quirin, T.; Varghese, F.S.; Žusinaite, E.; Das, P.K.; Ahola, T.; Merits, A. Chikungunya Virus Infectivity, RNA Replication and Non-Structural Polyprotein Processing Depend on the nsP2 Protease’s Active Site Cysteine Residue. Sci. Rep. 2016, 6, 37124. [Google Scholar] [CrossRef]
  49. Zhang, K.; Law, M.C.Y.; Nguyen, T.M.; Tan, Y.B.; Wirawan, M.; Law, Y.-S.; Jeong, L.S.; Luo, D. Molecular Basis of Specific Viral RNA Recognition and 5′-End Capping by the Chikungunya Virus nsP1. Cell Rep. 2022, 40, 111133. [Google Scholar] [CrossRef]
  50. Bartholomeeusen, K.; Utt, A.; Coppens, S.; Rausalu, K.; Vereecken, K.; Ariën, K.K.; Merits, A. A Chikungunya Virus Trans-Replicase System Reveals the Importance of Delayed Nonstructural Polyprotein Processing for Efficient Replication Complex Formation in Mosquito Cells. J. Virol. 2018, 92, e00152-18. [Google Scholar] [CrossRef]
  51. Andreev, D.E.; Terenin, I.M.; Dmitriev, S.E.; Shatsky, I.N. Pros and Cons of pDNA and mRNA Transfection to Study mRNA Translation in Mammalian Cells. Gene 2016, 578, 1–6. [Google Scholar] [CrossRef]
  52. Khan, K.H. Gene Expression in Mammalian Cells and Its Applications. Adv. Pharm. Bull. 2013, 3, 257–263. [Google Scholar] [CrossRef]
  53. Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA Vaccines—a New Era in Vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261–279. [Google Scholar] [CrossRef] [PubMed]
  54. Zarghampoor, F.; Azarpira, N.; Khatami, S.R.; Behzad-Behbahani, A.; Foroughmand, A.M. Improved Translation Efficiency of Therapeutic mRNA. Gene 2019, 707, 231–238. [Google Scholar] [CrossRef] [PubMed]
  55. Anderson, B.R.; Muramatsu, H.; Nallagatla, S.R.; Bevilacqua, P.C.; Sansing, L.H.; Weissman, D.; Karikó, K. Incorporation of Pseudouridine into mRNA Enhances Translation by Diminishing PKR Activation. Nucleic Acids Res. 2010, 38, 5884–5892. [Google Scholar] [CrossRef] [PubMed]
  56. Doublié, S.; Sawaya, M.R.; Ellenberger, T. An Open and Closed Case for All Polymerases. Structure 1999, 7, R31–R35. [Google Scholar] [CrossRef]
  57. Sesmero, E.; Thorpe, I.F. Using the Hepatitis C Virus RNA-Dependent RNA Polymerase as a Model to Understand Viral Polymerase Structure, Function and Dynamics. Viruses 2015, 7, 3974–3994. [Google Scholar] [CrossRef]
  58. Chen, Y.G.; Hur, S. Cellular Origins of dsRNA, Their Recognition and Consequences. Nat. Rev. Mol. Cell Biol. 2022, 23, 286–301. [Google Scholar] [CrossRef]
  59. Lemm, J.A.; Rice, C.M. Roles of Nonstructural Polyproteins and Cleavage Products in Regulating Sindbis Virus RNA Replication and Transcription. J. Virol. 1993, 67, 1916–1926. [Google Scholar] [CrossRef]
Viruses 17 01556 g001
Figure 1. CHIKV replicon used in this study. (A) Schematic of proposed alphavirus polyprotein processing pathways. Following entry and uncoating, the genomic RNA (gRNA) undergoes cap-dependent translation through both suppression and non-suppression mechanisms. Without suppression, translation terminates at the leaky opal stop codon at the end of nsP3, producing the P123 polyprotein, which undergoes cis-cleavage, yielding P12 and nsP3. P12 is further processed into nsP1 and nsP2. In the suppression pathway, opal read-through produces P1234, which is cleaved in stages to yield P12 and P34, and subsequently cleaved into nsP1/nsP2 and nsP3/nsP4. (B) Organization of the CHIKV genome and replicon (rCHIKV-sg-nLuc). The positive-strand RNA genome is capped at the 5′ end and polyadenylated at the 3′ end. ORF-1 encodes nsP1–4, followed by a 26S subgenomic promoter and ORF-2 encoding structural proteins (C, E3, E2, 6K, E1). The replicon replaces structural proteins with nanoluciferase (nLuc), expressed from the subgenomic RNA. (C) Promoter and cap analog comparison: SP6 promoter with ARCA (GA) vs. T7 promoter optimized for CleanCap (AU). (D) Chemical structures of ARCA and CleanCap AU used in in vitro transcription of replicons. (E) Comparison of capped rCHIKV-sg-nLuc RNAs. AU-capped RNAs yielded stronger luciferase signals relative to GA-capped transcripts. The GAA mutant of nsP4 (polymerase-inactive) produced only a background signal. (F) Fluorescent reporter version (rCHIKV-sg-UnaG), UnaG placed in ORF-2. Transfected HeLa cells displayed UnaG fluorescence (green), with tubulin immunostaining (magenta) marking cell boundaries. Mock controls lacked UnaG signal.
Figure 1. CHIKV replicon used in this study. (A) Schematic of proposed alphavirus polyprotein processing pathways. Following entry and uncoating, the genomic RNA (gRNA) undergoes cap-dependent translation through both suppression and non-suppression mechanisms. Without suppression, translation terminates at the leaky opal stop codon at the end of nsP3, producing the P123 polyprotein, which undergoes cis-cleavage, yielding P12 and nsP3. P12 is further processed into nsP1 and nsP2. In the suppression pathway, opal read-through produces P1234, which is cleaved in stages to yield P12 and P34, and subsequently cleaved into nsP1/nsP2 and nsP3/nsP4. (B) Organization of the CHIKV genome and replicon (rCHIKV-sg-nLuc). The positive-strand RNA genome is capped at the 5′ end and polyadenylated at the 3′ end. ORF-1 encodes nsP1–4, followed by a 26S subgenomic promoter and ORF-2 encoding structural proteins (C, E3, E2, 6K, E1). The replicon replaces structural proteins with nanoluciferase (nLuc), expressed from the subgenomic RNA. (C) Promoter and cap analog comparison: SP6 promoter with ARCA (GA) vs. T7 promoter optimized for CleanCap (AU). (D) Chemical structures of ARCA and CleanCap AU used in in vitro transcription of replicons. (E) Comparison of capped rCHIKV-sg-nLuc RNAs. AU-capped RNAs yielded stronger luciferase signals relative to GA-capped transcripts. The GAA mutant of nsP4 (polymerase-inactive) produced only a background signal. (F) Fluorescent reporter version (rCHIKV-sg-UnaG), UnaG placed in ORF-2. Transfected HeLa cells displayed UnaG fluorescence (green), with tubulin immunostaining (magenta) marking cell boundaries. Mock controls lacked UnaG signal.
Viruses 17 01556 g001
Viruses 17 01556 g002
Figure 2. Strategy to express CHIKV proteins to complement replicating subgenomic RNA replicons in trans. (A) (i) Design of a bicistronic (BiCis) mRNA containing a β-globin 5′UTR, ORF-A, EMCV IRES, eGFP, β-globin 3′UTR, and poly(A). (ii) BiCis-TagRFP-T produces TagRFP-T (cap-dependent) and eGFP (IRES-dependent). (iii) Representative fluorescence images at 4 h post-transfection in HeLa cells. TagRFP-T (red) and eGFP (green) display a robust signal. (B) (i) BiCis nLuc and Fluc constructs, either reporter placed in ORF-A. (ii) Reporter translation confirmed by luciferase assays in electroporated HeLa lysates. (C) Replicon competition assays: nLuc activity of rCHIKV-sg-nLuc WT or STOP2X ± BiCis TagRFP-T/eGFP. WT replicons produced robust nLuc activity regardless of co-expression; STOP2X yielded no signal. (D) Schematic of rCHIKV STOP2X, with two stop codons replacing the opal site, preventing nsP4 expression. STOP2X: nsP4 translation terminated by two stop codons replacing the opal codon at the end of the nsP3-coding region, producing P123 only.
Figure 2. Strategy to express CHIKV proteins to complement replicating subgenomic RNA replicons in trans. (A) (i) Design of a bicistronic (BiCis) mRNA containing a β-globin 5′UTR, ORF-A, EMCV IRES, eGFP, β-globin 3′UTR, and poly(A). (ii) BiCis-TagRFP-T produces TagRFP-T (cap-dependent) and eGFP (IRES-dependent). (iii) Representative fluorescence images at 4 h post-transfection in HeLa cells. TagRFP-T (red) and eGFP (green) display a robust signal. (B) (i) BiCis nLuc and Fluc constructs, either reporter placed in ORF-A. (ii) Reporter translation confirmed by luciferase assays in electroporated HeLa lysates. (C) Replicon competition assays: nLuc activity of rCHIKV-sg-nLuc WT or STOP2X ± BiCis TagRFP-T/eGFP. WT replicons produced robust nLuc activity regardless of co-expression; STOP2X yielded no signal. (D) Schematic of rCHIKV STOP2X, with two stop codons replacing the opal site, preventing nsP4 expression. STOP2X: nsP4 translation terminated by two stop codons replacing the opal codon at the end of the nsP3-coding region, producing P123 only.
Viruses 17 01556 g002
Viruses 17 01556 g003
Figure 3. Expression of CHIKV P123 and P34 is sufficient for subgenomic RNA synthesis. (A) rCHIKV STOP2X lacks nsP4, producing P123 alone; BiCis P34 provides nsP4 in the form of P34 (plus eGFP marker). (B) Complementation assay schematic: co-transfection allows P123 + P34 to drive RNA replication and nLuc expression, * end of nsP4 region in subgenomic mRNA. (C) nLuc activity: STOP2X complemented with P34 WT restoring replication; P34-GAA (inactive RdRp) failed. (D) P34 titration: graded P34 RNA doses supported subgenomic RNA synthesis, with Fluc RNA included to equalize RNA input. (E) Mutagenesis of the nsP3-nsP4 conserved junction among alphaviruses prevents cleavage (VGY or GVY mutants), * fully conserved residue, : strong conservation, . weak conservation, (space) not conserved. (F) These uncleavable P34 variants failed to complement STOP2X.
Figure 3. Expression of CHIKV P123 and P34 is sufficient for subgenomic RNA synthesis. (A) rCHIKV STOP2X lacks nsP4, producing P123 alone; BiCis P34 provides nsP4 in the form of P34 (plus eGFP marker). (B) Complementation assay schematic: co-transfection allows P123 + P34 to drive RNA replication and nLuc expression, * end of nsP4 region in subgenomic mRNA. (C) nLuc activity: STOP2X complemented with P34 WT restoring replication; P34-GAA (inactive RdRp) failed. (D) P34 titration: graded P34 RNA doses supported subgenomic RNA synthesis, with Fluc RNA included to equalize RNA input. (E) Mutagenesis of the nsP3-nsP4 conserved junction among alphaviruses prevents cleavage (VGY or GVY mutants), * fully conserved residue, : strong conservation, . weak conservation, (space) not conserved. (F) These uncleavable P34 variants failed to complement STOP2X.
Viruses 17 01556 g003
Viruses 17 01556 g004
Figure 4. Identification of a minimal P34 precursor for subgenomic RNA synthesis. (A) Schematic of extended nsP4 constructs lacking domains of nsP3—macro domain (MD), alphavirus unique domain (AUD), and partial hyper-variable domain (HVD)—which produce CT150, CT50, or CT39-P34. (B) Complementation assays: STOP2X supported subgenomic RNA synthesis with P34 WT, CT150, and CT50, and partially with CT39-P34.
Figure 4. Identification of a minimal P34 precursor for subgenomic RNA synthesis. (A) Schematic of extended nsP4 constructs lacking domains of nsP3—macro domain (MD), alphavirus unique domain (AUD), and partial hyper-variable domain (HVD)—which produce CT150, CT50, or CT39-P34. (B) Complementation assays: STOP2X supported subgenomic RNA synthesis with P34 WT, CT150, and CT50, and partially with CT39-P34.
Viruses 17 01556 g004
Viruses 17 01556 g005
Figure 5. Ub-nsP4 fusions do substitute for P34 when expressed transiently. (A) Schematic of nsP4 constructs included: Met•Tyr•nsP4 (*methionine incorporated from Kozak sequence), Ub-Tyr•nsP4 (cleavable), and Ub*-Tyr•nsP4 (*uncleavable), P34-WT and P34 (GAA). (B) Complementation assays: STOP2X was partially and inefficiently rescued by Ub-Tyr•nsP4 but not by Met•Tyr•nsP4 or Ub*-Tyr•nsP4. The y-axis is split into two ranges to highlight the slight increase in activity exhibited by Ub-Tyr•nsP4 (10 hpt) compared to P34-WT (positive control).
Figure 5. Ub-nsP4 fusions do substitute for P34 when expressed transiently. (A) Schematic of nsP4 constructs included: Met•Tyr•nsP4 (*methionine incorporated from Kozak sequence), Ub-Tyr•nsP4 (cleavable), and Ub*-Tyr•nsP4 (*uncleavable), P34-WT and P34 (GAA). (B) Complementation assays: STOP2X was partially and inefficiently rescued by Ub-Tyr•nsP4 but not by Met•Tyr•nsP4 or Ub*-Tyr•nsP4. The y-axis is split into two ranges to highlight the slight increase in activity exhibited by Ub-Tyr•nsP4 (10 hpt) compared to P34-WT (positive control).
Viruses 17 01556 g005
Viruses 17 01556 g006
Figure 6. Proposed model for an nsP4 precursor role in CHIKV RNA synthesis. (A) P34 and functional derivatives (CT50-P34) bind to the central channel of an nsP1 dodecamer. The CT50 portion of P34 is highlighted in orange, and P4 in black. (B) nsP2 cleaves the (nsP1)12-bound P34, activating its RdRp activity. Physical interactions between nsP4 and (nsP1)12 maintain nsP4 in its active compact conformation. (C) Once RNA synthesis is complete, dissociation of nsP4 from (nsP1)12 causes a fold switch to the extended, inactive extended conformation. Model built using ONNV CT50-P34 Alphafold/SAXS-derived structure (bioRxiv:2025.09.18.676892 [18]) and nsP1 structure (PDB: 7Y38).
Figure 6. Proposed model for an nsP4 precursor role in CHIKV RNA synthesis. (A) P34 and functional derivatives (CT50-P34) bind to the central channel of an nsP1 dodecamer. The CT50 portion of P34 is highlighted in orange, and P4 in black. (B) nsP2 cleaves the (nsP1)12-bound P34, activating its RdRp activity. Physical interactions between nsP4 and (nsP1)12 maintain nsP4 in its active compact conformation. (C) Once RNA synthesis is complete, dissociation of nsP4 from (nsP1)12 causes a fold switch to the extended, inactive extended conformation. Model built using ONNV CT50-P34 Alphafold/SAXS-derived structure (bioRxiv:2025.09.18.676892 [18]) and nsP1 structure (PDB: 7Y38).
Viruses 17 01556 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Aponte-Diaz, D.; Jain, A.; Harris, J.M.; Arnold, J.J.; Cameron, C.E. Minimal Polymerase-Containing Precursor Required for Chikungunya Virus RNA Synthesis. Viruses 2025, 17, 1556. https://doi.org/10.3390/v17121556

AMA Style

Aponte-Diaz D, Jain A, Harris JM, Arnold JJ, Cameron CE. Minimal Polymerase-Containing Precursor Required for Chikungunya Virus RNA Synthesis. Viruses. 2025; 17(12):1556. https://doi.org/10.3390/v17121556

Chicago/Turabian Style

Aponte-Diaz, David, Abha Jain, Jayden M. Harris, Jamie J. Arnold, and Craig E. Cameron. 2025. "Minimal Polymerase-Containing Precursor Required for Chikungunya Virus RNA Synthesis" Viruses 17, no. 12: 1556. https://doi.org/10.3390/v17121556

APA Style

Aponte-Diaz, D., Jain, A., Harris, J. M., Arnold, J. J., & Cameron, C. E. (2025). Minimal Polymerase-Containing Precursor Required for Chikungunya Virus RNA Synthesis. Viruses, 17(12), 1556. https://doi.org/10.3390/v17121556

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop